Ildong Pharmaceutical Co., Ltd. (249420.KS)
KRW 11350.0
(-5.42%)
KRW 11350.0
(-5.42%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 260.95 Billion KRW | -15.73% |
| 2022 | 309.67 Billion KRW | 13.1% |
| 2021 | 273.81 Billion KRW | 18.14% |
| 2020 | 231.78 Billion KRW | -0.83% |
| 2019 | 233.72 Billion KRW | 3.05% |
| 2018 | 226.81 Billion KRW | 12.92% |
| 2017 | 200.86 Billion KRW | 143.47% |
| 2016 | 82.5 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 56.14 Billion KRW | -1.55% |
| 2024 Q3 | 152.34 Billion KRW | -4.89% |
| 2024 Q1 | 57.02 Billion KRW | 2.29% |
| 2023 Q2 | -74.86 Billion KRW | -208.96% |
| 2023 Q3 | -66.87 Billion KRW | 10.67% |
| 2023 Q4 | 55.75 Billion KRW | 183.37% |
| 2023 FY | 260.95 Billion KRW | -15.73% |
| 2023 Q1 | 68.7 Billion KRW | -12.15% |
| 2022 Q4 | 78.21 Billion KRW | -1.67% |
| 2022 Q3 | 79.54 Billion KRW | -4.31% |
| 2022 Q2 | 83.12 Billion KRW | 20.83% |
| 2022 Q1 | 68.79 Billion KRW | -1.38% |
| 2022 FY | 309.67 Billion KRW | 13.1% |
| 2021 Q4 | 69.75 Billion KRW | -4.12% |
| 2021 Q2 | 66.51 Billion KRW | 2.68% |
| 2021 Q3 | 72.75 Billion KRW | 9.38% |
| 2021 FY | 273.81 Billion KRW | 18.14% |
| 2021 Q1 | 64.78 Billion KRW | 2.43% |
| 2020 FY | 231.78 Billion KRW | -0.83% |
| 2020 Q4 | 63.24 Billion KRW | 13.61% |
| 2020 Q3 | 55.66 Billion KRW | -4.88% |
| 2020 Q1 | 54.35 Billion KRW | -6.92% |
| 2020 Q2 | 58.51 Billion KRW | 7.67% |
| 2019 FY | 233.72 Billion KRW | 3.05% |
| 2019 Q2 | 59.54 Billion KRW | 7.65% |
| 2019 Q3 | 60.47 Billion KRW | 1.56% |
| 2019 Q4 | 58.39 Billion KRW | -3.44% |
| 2019 Q1 | 55.31 Billion KRW | -2.27% |
| 2018 Q4 | 56.59 Billion KRW | -7.01% |
| 2018 Q1 | 53.27 Billion KRW | 5.91% |
| 2018 Q2 | 56.07 Billion KRW | 5.26% |
| 2018 FY | 226.81 Billion KRW | 12.92% |
| 2018 Q3 | 60.86 Billion KRW | 8.53% |
| 2017 Q3 | 52.72 Billion KRW | 4.65% |
| 2017 Q2 | 50.37 Billion KRW | 6.14% |
| 2017 FY | 200.86 Billion KRW | 143.47% |
| 2017 Q4 | 50.29 Billion KRW | -4.6% |
| 2017 Q1 | 47.46 Billion KRW | -1.99% |
| 2016 Q4 | 48.43 Billion KRW | 42.13% |
| 2016 FY | 82.5 Billion KRW | 0.0% |
| 2016 Q3 | 34.07 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -452.242% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 12.428% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 6.279% |
| HANDOK Inc. | 153.76 Billion KRW | -69.707% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -277.03% |
| Yuhan Corporation | 489.94 Billion KRW | 46.738% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 14.986% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -524.453% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 57.288% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -262.522% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -49.847% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -551.524% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | -178.943% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | -127.462% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -452.242% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -514.422% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -247.713% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -344.981% |
| JW Holdings Corporation | 301.25 Billion KRW | 13.378% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 36.143% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -9.227% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -104.4% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -282.012% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -296.883% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | -49.181% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -452.242% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | -4.75% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 53.437% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -9.227% |
| Yuhan Corporation | 489.94 Billion KRW | 46.738% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | -34.747% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -275.646% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -365.726% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -9.227% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | -106.464% |
| Korea United Pharm Inc. | 118.21 Billion KRW | -120.749% |
| CKD Bio Corp. | 25.19 Billion KRW | -935.714% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | -17.548% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | -58.047% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -292.903% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -104.4% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 25.593% |
| Boryung Corporation | 285.16 Billion KRW | 8.489% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -198.092% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -49.847% |
| JW Lifescience Corporation | 20.26 Billion KRW | -1187.935% |